Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140120 · ClinicalTrials.gov registry record
LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study
A clinical trial of Cirrhosis, Liver and Portal Hypertension, sponsored by University of Michigan.
- Active
- Registry status
- 52
- Enrollment target
- 3
- Study locations
NCT07140120: Active study of Cirrhosis, Liver and Portal Hypertension, sponsored by University of Michigan.
NCT07140120 is a study of Cirrhosis, Liver and Portal Hypertension that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 52 participants, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07140120, a study of Cirrhosis, Liver and Portal Hypertension, is active but no longer recruiting, sponsored by University of Michigan.
- ACTIVE NOT RECRUITING
- Registry status
- 52 participants
- Enrollment target
- 3
- Study locations
Study Summary
The LIVE-SMART supplementary study will assess social determinants of health (income, education, neighborhood deprivation), financial burden (out-of-pocket costs, productivity loss), financial distress (patient and caregiver-reported outcomes), and financial toxicity (healthcare utilization) among LIVE-SMART participants and their caregivers. Participants for this supplementary study are participants in the primary study (NCT05794555) and their caregivers.
Primary Outcome
Financial toxicity will be measured using the COST-FACIT v2 tool, a 12-item, validated self-reported scale validated reflecting experiences of the prior 7-days scored 0-44 (with higher scores indicating more toxicity).
Conditions Studied
Study Locations (3)
Michigan
- University of Michigan - Ann Arbor
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- Baylor Scott & White Research Institute (BSW) - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2026-06 |
What the registry record for NCT07140120 still lists
NCT07140120 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 0 interventions.
NCT07140120 reports a single indexed study location in Michigan, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT07140120 about?
NCT07140120 is a clinical study titled "LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study". The LIVE-SMART supplementary study will assess social determinants of health (income, education, neighborhood deprivation), financial burden (out-of-pocket costs, productivity loss), financial distress (patient and caregiver-reported outcomes), and financial toxicity (healthcare utilization) among L...
What is the current status of trial NCT07140120?
This trial is currently active not recruiting. The enrollment target is 52 participants. The study started on 2023-06-13. Estimated completion is 2026-06.
What conditions does trial NCT07140120 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Portal Hypertension.
Who is sponsoring clinical trial NCT07140120?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07140120 being conducted?
This trial has 3 study locations across Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07140120's enrollment target sits among peer trials
52 21st of 34 higher than 14 of 34 other Cirrhosis, Liver trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cirrhosis, Liver trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
RECRUITING · Phase 1
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Measuring Patient Reported Needs in Outpatient Liver Disease Management
RECRUITING
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI